Mirum Pharmaceuticals, Inc.
MIRM
$67.72
-$2.37-3.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 58.50% | 46.35% | 51.22% | 46.18% | 39.21% |
| Total Depreciation and Amortization | 7.99% | 26.01% | 60.82% | 118.21% | 262.41% |
| Total Amortization of Deferred Charges | 4.56% | 4.23% | 9.73% | 48.70% | 128.97% |
| Total Other Non-Cash Items | 17.33% | 18.79% | -42.14% | -50.54% | -36.65% |
| Change in Net Operating Assets | -143.92% | -267.27% | -272.03% | 217.53% | 181.16% |
| Cash from Operations | 3,748.33% | 138.39% | 81.47% | 114.55% | 98.62% |
| Capital Expenditure | 61.56% | 53.54% | -1,160.49% | -811.01% | -177.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.91% | 9.51% | -233.85% | -184.35% | -168.16% |
| Cash from Investing | 73.78% | 84.42% | 20.85% | 15.93% | -18.26% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 153.06% | -88.86% | -89.25% | -92.21% | -93.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 99.86% |
| Cash from Financing | 158.09% | -88.85% | -92.96% | -94.74% | -95.77% |
| Foreign Exchange rate Adjustments | 1,084.74% | 1,034.27% | -70.67% | -875.19% | 221.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.19% | 92.32% | -159.05% | -140.04% | -147.62% |